Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | CLK1 | P49759 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | PRKX | P51817 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224605 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2ROCK2ROCK1LMNAHPGD | |
| SCHEMBL357618 | 0.80 | TSHR (0.53) | SMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL30309985 | 0.80 | SMN1; SMN2 (0.74) | SMN1; SMN2ROCK2ROCK1LMNAHPGD | |
| SCHEMBL14917101 | 0.77 | DHX9 (0.69) | SMN1; SMN2ROCK1LMNACLK1DHX9 | |
| SCHEMBL13211939 | 0.77 | SMN1; SMN2 (0.76) | SMN1; SMN2LMNAHPGDMMP13CLK1 | |
| SCHEMBL9416647 | 0.77 | ROCK2 (0.65) | ROCK2ROCK1LMNAHPGDMMP13 | |
| SCHEMBL5724150 | 0.76 | ROCK2 (0.68) | ROCK2ROCK1HPGDSRCPPARG | |
| SCHEMBL360181 | 0.75 | ROCK2 (0.65) | ROCK2ROCK1SRC | |
| SCHEMBL14789741 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2ROCK2LMNAHPGDKLKB1 | |
| SCHEMBL31260035 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2ROCK2LMNAHPGDKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885ROCK2 3534/4885ROCK1 2764/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885ROCK2 3534/4885ROCK1 2764/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885ROCK2 3534/4885ROCK1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.